Expression_NN
status_NN
of_IN
BCL-6_NN
and_CC
syndecan-1_NN
identifies_VBZ
distinct_JJ
histogenetic_JJ
subtypes_NNS
of_IN
Hodgkin_NN
's_POS
disease_NN
._.

The_DT
tumor_NN
cells_NNS
in_IN
most_JJS
cases_NNS
of_IN
Hodgkin_NN
's_POS
disease_NN
-LRB-_-LRB-
HD_NN
-RRB-_-RRB-
have_VBP
been_VBN
recently_RB
recognized_VBN
to_TO
originate_VB
from_IN
the_DT
B-cell_NN
lineage_NN
,_,
but_CC
their_PRP$
precise_JJ
differentiation_NN
stage_NN
is_VBZ
not_RB
fully_RB
clarified_VBN
._.

Recently_RB
,_,
we_PRP
have_VBP
reported_VBN
that_IN
the_DT
histogenesis_NN
of_IN
B-cell_NN
lymphomas_NNS
may_MD
be_VB
assessed_VBN
by_IN
monitoring_VBG
the_DT
expression_NN
pattern_NN
of_IN
BCL-6_NN
,_,
a_DT
transcription_NN
factor_NN
expressed_VBN
in_IN
germinal_JJ
center_NN
-LRB-_-LRB-
GC_NN
-RRB-_-RRB-
B_NN
cells_NNS
,_,
and_CC
CD138\/syndecan_NN
-1_CD
-LRB-_-LRB-
syn-1_NN
-RRB-_-RRB-
,_,
a_DT
proteoglycan_NN
associated_VBN
with_IN
post-GC_JJ
,_,
terminal_JJ
B-cell_NN
differentiation_NN
._.

In_IN
this_DT
study_NN
,_,
we_PRP
have_VBP
applied_VBN
these_DT
two_CD
markers_NNS
to_TO
the_DT
study_NN
of_IN
HD_NN
histogenesis_NN
._.

We_PRP
have_VBP
found_VBN
that_IN
in_IN
nodular_JJ
lymphocyte_NN
predominance_NN
HD_NN
-LRB-_-LRB-
NLPHD_NN
-RRB-_-RRB-
tumor_NN
cells_NNS
consistently_RB
display_VBP
the_DT
BCL-6_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
\/_:
syn-1_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
phenotype_NN
,_,
indicating_VBG
their_PRP$
derivation_NN
from_IN
GC_NN
B_NN
cells_NNS
._.

Conversely_RB
,_,
classic_JJ
HD_NN
-LRB-_-LRB-
CHD_NN
-RRB-_-RRB-
is_VBZ
heterogeneous_JJ
because_IN
the_DT
tumor_NN
cells_NNS
of_IN
a_DT
fraction_NN
of_IN
CHD_NN
display_VBP
the_DT
BCL-6_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
\/_:
syn-1_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
phenotype_NN
of_IN
post-GC_JJ
B-cells_NNS
,_,
whereas_IN
another_DT
fraction_NN
of_IN
CHD_NN
is_VBZ
constituted_VBN
by_IN
a_DT
mixture_NN
of_IN
tumor_NN
cells_NNS
reflecting_VBG
the_DT
GC_NN
-LRB-_-LRB-
BCL-6_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
\/_:
syn-1_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
-RRB-_-RRB-
or_CC
post-GC_JJ
-LRB-_-LRB-
BCL-6_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
\/_:
syn-1_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
-RRB-_-RRB-
phenotypes_NNS
._.

BCL-6_NN
-LRB-_-LRB-
-_NN
-RRB-_-RRB-
\/_:
syn-1_NN
-LRB-_-LRB-
+_NN
-RRB-_-RRB-
tumor_NN
cells_NNS
of_IN
CHD_NN
are_VBP
mostly_RB
found_VBN
surrounded_VBN
by_IN
T_NN
cells_NNS
expressing_VBG
CD40L_NN
,_,
consistent_JJ
with_IN
the_DT
observation_NN
that_IN
CD40_NN
signaling_NN
downregulates_VBZ
BCL-6_NN
expression_NN
._.

These_DT
data_NNS
indicate_VBP
that_IN
tumor_NN
cells_NNS
of_IN
NLPHD_NN
uniformly_RB
display_VBP
a_DT
GC_NN
B-cell_NN
phenotype_NN
,_,
whereas_IN
the_DT
phenotype_NN
of_IN
tumor_NN
cells_NNS
of_IN
CHD_NN
appears_VBZ
to_TO
be_VB
modulated_VBN
by_IN
the_DT
surrounding_JJ
cellular_JJ
background_NN
,_,
particularly_RB
CD40L_NN
+_CC
reactive_JJ
T_NN
cells_NNS
._.

